ReviewClinical & experimental ophthalmology2025
Minimally Invasive Glaucoma Surgery: Is It Here to Stay?
Review in Clinical & experimental ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Minimally Invasive Glaucoma Surgery: Is It Here to Stay?Clinical & experimental ophthalmology · 2025Review
- Intravitreal drug injection for glaucoma: mechanisms, clinical efficacy, and future horizons.Frontiers in pharmacology · 2025Review
- Insights and decision-making on surgical triggers of glaucoma-related complications in congenital cataract surgery: a clinical review.Frontiers in medicine · 2025Review
- Gel-based Ocular Phantom Models in Glaucoma Diagnostics: A Bibliometric and Narrative Review.Journal of current glaucoma practiceReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The advent of minimally invasive glaucoma surgery (MIGS) has expanded the treatment options available for glaucoma by providing options for reducing intraocular pressure without the serious complication profile associated with incisional glaucoma surgery. MIGS devices aim to enhance aqueous outflow through the trabecular pathway or to bypass this pathway with drainage of fluid into the suprachoroidal or subconjunctival spaces. Having a wide range of glaucoma treatment options available helps tailor treatment to patients' individual intraocular pressure targets and aetiologies of glaucoma. This review will describe the categories and mechanisms of MIGS, comment on their relative efficacies, safety data, advantages and limitations and explore potential future changes in the glaucoma treatment paradigm in relation to MIGS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.